{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/1138356"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "GEN's products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products fro" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "presseportal.de" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/398237997"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/1138356" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/155551075"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/1138356"] } } }
